Jane Huang

Dr. Jane Huang has served on Protara’s board of directors since June 2021. Dr. Huang is an experienced biotech executive and proven leader throughout the development lifecycle of multiple oncology therapeutics globally. She currently serves as Chief Medical Officer, Hematology at BeiGene, Ltd. At BeiGene, Dr. Huang oversees hematology drug development and played a key role in the first approval of tislelizumab, BeiGene’s PD-1 inhibitor as well as zanubrutinib, BeiGene’s BTK inhibitor. Prior to joining BeiGene, Dr. Huang was Vice President and Head of Development at Acerta Pharma, where she oversaw the global clinical development of the BTK inhibitor acalabrutinib. Previously, she served as Group Medical Director at Genentech where she played a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. Dr. Huang also currently serves as a Clinical Assistant Professor (adjunct), Thoracic Oncology, at Stanford University. She received her Bachelor of Science degree in Biological Sciences from Stanford University and her M.D. from the University of Washington School of Medicine. She is board certified in hematology, oncology, and internal medicine, and she completed her residency in Internal Medicine and fellowships in Hematology and Oncology at Stanford University.